TX000045 (TX45)
Heart Failure with Preserved Ejection Fraction (HFpEF) / Group 2 Pulmonary Hypertension
Phase 1Active
Key Facts
Indication
Heart Failure with Preserved Ejection Fraction (HFpEF) / Group 2 Pulmonary Hypertension
Phase
Phase 1
Status
Active
Company
About Tectonic Therapeutic
Tectonic Therapeutic is a clinical-stage biotech focused on unlocking the vast therapeutic potential of G-Protein Coupled Receptors (GPCRs) through its proprietary GEODe™ platform for biologic drug discovery. Founded on foundational research from Harvard Medical School and led by a deeply experienced pharmaceutical R&D team, the company's mission is to develop transformative medicines for cardiopulmonary and fibrotic diseases. Its strategy centers on advancing its lead Fc-relaxin fusion program, TX000045, through clinical proof-of-concept while leveraging its platform to build a pipeline of novel GPCR-targeted biologics.
View full company profile